In a more recent study, combining daratumumab with a CD47-blocking antibody substantially prolonged survival as compared to single treatments, and it was hypothesized that the CD47 blockade was able to overcome the immunosuppressive effects on ADCP mediated by dysregulated CD38 expression in T-ALL [84]. The gene discussed is CD47; the disease is acute lymphoblastic leukemia.